Project Details
Description
DESCRIPTION (Adapted from the Investigator's abstract): This renewal
application seeks to continue studies on the regulation of B-cell lymphoma
growth and apoptosis. The investigator's laboratory has found that anti-Mu,
but not anti-delta, treatment of a set of lymphomas in early G1 results in
arrest of their growth prior to the G1/S border and then apoptosis. They
have found that the initial step is activation of src family protein
tyrosine kinases, which promote the docking and phosphorylation of second
messenger substrates. During this process synthesis of c-myc transiently
appears and disappears. It is now clear that this growth arrest results
from action of anti-Mu on components of the kinase:cyclin complexes that
regulate phosphorylation of the retinoblastoma gene product, pRb. In the
continuing investigation the overall goal will be to connect the initial
tyrosine phosphorylation events to altered myc transcription and
modification of the cyclin:cdk complexes that act on pRb. This will be done
using a series of CD8 chimeric proteins and mutant constructs to identify
downstream substrates for phosphorylation by Ig-associated co-receptors,
Ig-alpha and Ig-beta. The nature of the cyclin:cdk complexes that are
targeted by anti-Mu will be determined using elutriator purified G1 lymphoma
cells. In addition, E2F, which is bound by pRb, will be over-expressed to
determine whether cell cycle arrest is required for induction of apoptosis.
The effect of anti-mu on localization and activity of myc will be studied
based on the idea that this molecule plays a critical role in the balance
between cell cycle progression and apoptosis. Finally, the points at which
T-cell signals interfere with apoptosis-inducing signals with be examined,
since these can prevent anti-Mu induced apoptosis in these lymphomas. The
results of these studies will provide information on regulation of
neoplastic growth as well as mechanism for inducing apoptosis in a model for
deletional tolerance.
Status | Finished |
---|---|
Effective start/end date | 1/05/92 → 30/04/02 |
Funding
- National Cancer Institute: $76,973.00
- National Cancer Institute: $76,973.00
- National Cancer Institute: $290,979.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.